Uptake and metabolism of arginine impact Plasmodium development in the liver

Patrícia Meireles1, António M Mendes1, Rita I Aroeira1,2

  • 1Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal.

Scientific Reports
|June 24, 2017
PubMed

Insights

L-arginine uptake via host SLC7A2 transporters fuels Plasmodium parasite growth in the liver. This nutrient fuels polyamine production, crucial for parasite development and a potential target for malaria control.

Area of Science:

  • Parasitology
  • Molecular Biology
  • Malaria Research

Background:

  • Plasmodium parasites infect the liver before causing malaria symptoms.
  • Intrahepatic parasite development requires nutrient acquisition for growth and multiplication.
  • Understanding nutrient dependency is key to targeting early-stage malaria infection.

Purpose of the Study:

  • To investigate the role of L-arginine (Arg) uptake in Plasmodium intrahepatic development.
  • To elucidate the metabolic pathways utilized by the parasite for nutrient utilization in the liver.
  • To identify potential therapeutic targets for blocking liver-stage malaria infection.

Main Methods:

  • Analysis of L-arginine uptake in host liver cells infected with Plasmodium parasites.
  • Investigating the function of SLC7A2 transporters in parasite nutrient acquisition.
  • Metabolic profiling to identify pathways involved in polyamine synthesis from L-arginine.

Main Results:

  • L-arginine uptake through host SLC7A2 transporters is essential for Plasmodium liver-stage development.
  • Metabolism of L-arginine via the arginase pathway produces polyamines critical for parasite growth.
  • Plasmodium parasites primarily utilize their own arginase-AdoMetDC/ODC pathway for polyamine synthesis.

Conclusions:

  • L-arginine-dependent polyamine production is pivotal for Plasmodium hepatic development.
  • Targeting L-arginine uptake and polyamine synthesis pathways offers a novel strategy against liver-stage malaria.
  • This study identifies a critical nutrient dependency for blocking malaria transmission.

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
267
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
302
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
289
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
316
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
244
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance01:07

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
354